Plus Therapeutics receives Nasdaq extension until March 4, 2025 to regain minimum equity compliance

PLUS THERAPEUTICS, INC.

Nasdaq Hearings Panel granted extension to March 4, 2025 for Plus Therapeutics to meet $2.5M stockholders' equity minimum.
Company has been non-compliant since March 8, 2024; hearing was held on October 22, 2024.
No assurance of regaining compliance; delisting risk remains if equity condition not met by deadline.
Stock continues trading on Nasdaq Capital Market under ticker PSTV during extension period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.